ABOUT THE

LILLY NCD

PARTNERSHIP

THE LILLY NCD PARTNERSHIP

In September 2011, we announced the launch of the Lilly NCD Partnership, a major corporate responsibility initiative to address the global health crisis of non-communicable diseases (NCDs). This global health partnership is Lilly’s response to the urgent need for solutions to address NCDs — diseases such as diabetes — in four selected emerging economies.

Lilly has committed US$30 million over five years to fight the rising burden of NCDs in emerging economies. The Lilly NCD Partnership combines the company’s unique resources with the expertise of leading global health organizations, to identify new models of patient care that increase treatment access and improve outcomes for people in need.

The Lilly NCD Partnership focuses on improving diabetes care in targeted communities in Brazil, India, Mexico and South Africa. Specifically, we are:

  • Strengthening diabetes care capabilities at primary care health clinics
  • Improving system efficiencies so that more people with diabetes can receive effective care
  • Increasing appropriate use and medication compliance to improve patient outcomes
  • Supporting replication of successful efforts in similar clinical environments

Financials

Reported cases of diabetes have more than doubled in the past three decades: 347 million people worldwide have diabetes, up from 153 million in 1980, and this figure is projected to rise to 472 million by 2030 — 80% of these cases will be in low- and middle-income countries.

WHY DIABETES?

For more than 90 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world’s first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes.

While we and other biopharmaceutical companies have made tremendous inroads, diabetes continues to ravage families and communities, especially in emerging economies. Given our deep expertise, medicines and pipeline, diabetes is a natural fit for the Lilly NCD Partnership.